News Releases
View all Historical Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 9, 2017
PRINCETON, NJ – November 9, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Nov 6, 20172017 Non-Dilutive Funding Exceeds $8M
PRINCETON, NJ – November 6, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Nov 3, 2017
PRINCETON, NJ – November 3, 2017 – Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 31, 2017
PRINCETON, NJ – October 31, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 24, 2017
PRINCETON, NJ – October 24, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 17, 2017
Princeton, NJ – October 17, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Oct 5, 2017
PRINCETON, NJ – October 5, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Sep 25, 20172017 Non-Dilutive Funding Exceeds $8M
PRINCETON, NJ – September 25, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Sep 20, 20172017 Non-Dilutive Funding Reaches $7.5 Million
PRINCETON, NJ – September 20, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Sep 18, 20172017 Non-Dilutive Funding Climbs to $6 Million
PRINCETON, NJ – September 18, 2017 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...